StockUK listing UK0DHCLSEBalanced

Carl Zeiss Meditec AG(0DHC) Stock Analysis

EUR --+0.00%
Reward53Moderate
Risk45Moderate
50%Data
EUR —+0.00 (+0.00%) Previous close · LSE
Market cap 12.18Bn
Reward Ratingⓘ53 Moderate reward assessment · 50% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ45 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0DHC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Carl Zeiss Meditec AG?

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia.

AI Brief Pro

The brief on Carl Zeiss Meditec AG

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Carl Zeiss Meditec AG?

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The company is listed on the LSE in UK, with a market capitalisation of 12.18B, and a P/E ratio of 0.5x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (53)
Company Information
SectorN/A
IndustryN/A
P/E Ratio0.4595
Beta1.355
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.